CD19 and acute lymphoblastic leukemia: In 2018, FDA approved the anti-CD19 CART cell therapy tisagenlecleucel (CTL019) for R/R B-ALL based on the results of the ELIANA multicenter study (ClinicalTrials.gov number, new cases and 1560 deaths (incluNCT02435849), which showed high response rates in patients up to 25 years of age.